HLB Pharma Amends Paid-in Capital Increase Schedule
HLB제약
047920
Signal Score
Historical Avg Return (5d)
+0.33%
Data Coverage
100%n=2377
Risk-adjusted indicator based on 2377 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares to be Issued: 10,762,332 Shares
- • Share Allotment Ratio per Existing Share: 0.3281321329 Shares
- • Dilution Rate: 32.81%
- • Old Shareholder Subscription Period (Revised): September 10-11, 2026
- • Final Issue Price Determination Date (Revised): September 8, 2026
AI Analysis Summary
HLB Pharmaceutical announced an amendment to its paid-in capital increase plan, primarily adjusting the schedule. The number of new shares to be issued remains 10,762,332, resulting in a dilution rate of 32.81%. The final issue price will be determined on September 8, 2026, with existing shareholder subscriptions now scheduled for September 10-11, 2026. The purpose of the funds was not detailed in this amendment. The delay in the schedule might introduce minor uncertainty, but the core terms of the capital increase remain unchanged, indicating a neutral to slightly negative short-term impact due to prolonged uncertainty.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.